Chapter 10 Limited expression of myeloid antigens by neuroendocrine tumours of lung

Frozen sections of small cell lung carcinoma (SCLC) and bronchial carcinoid (BC) and cytospins of the SCLC lines, NCI-H69, NCI-H128 and NCI-H146, were stained with antibodies of the myeloid-monocyte panel assembled by the Third International Workshop on Human Leucocyte Differentiation Antigens by a sensitive alkaline phosphatase-antialkaline phosphatase technique. Two SCLC, one BC and two cell lines were screened with full panel of 145 antibodies. To assess the heterogeneity of expression of leucocyte antigens, antibodies of defined clusters, provisional groups and single unclustered antibodies which were immunoreactive on the initial screen were further tested against a total of 8 SCLC, 3 BC and 3 cell lines. SCLC expressed CD epitopes frequently, with 5 of 8 tumours reacting with one or more of the 14 CD15 antibodies in the panel. No other established CD cluster reacted consistently with SCLC but at least one antibody of provisional group (G) 10 reacted focally with a few of the SCLC tested. Each of the BC reacted with at least one of the CD15 antibodies but labeling reactions of BC differed from those of SCLC in that CD13 epitopes were found on all of the tumours tested. In addition, BC were labelled with broader range of provisional group antibodies including G10, G11, G12, G14 and G15. Many antibodies which could not be clustered at the Workshop labelled both SCLC and BC. These Studies suggest that X-hapten (CD15) is frequently expressed in neuroendocrine tumours of lung and that CD13 antigen and several provisional group antigens are more commonly expressed in BC than in SCLC. Other well defined myelomonocytic epitopes are rarely found on neuroendocrine lung tumour cells. © 1988 Elsevier Science Publishers B.V. (Biomedical Division). All rights reserved.

Duke Scholars

Author Joseph Geradts Pathology